Also, we do not know the effects of expressing mutant oncogenes, Kras or others, or tumour suppressors on the likelihood of KACs to divert away from mediating AT1 regeneration and, instead, transition to tumour cells. The gene discussed is KRAS; the disease is neoplasm.